DRAQ7 overcomes the complications associated with autofluorescence of doxorubicin during flow cytometric analyses

Clicks: 1
ID: 314598
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #1 of 20 articles by views in Biology Methods and Protocols

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Doxorubicin (DOX) is a widely used chemotherapeutic agent that induces apoptosis through DNA intercalation, topoisomerase II inhibition, and oxidative stress. However, its cardiotoxicity is a significant concern. Flow cytometry, particularly with Annexin V/propidium iodide (PI) or Annexin V/7AAD assays, is commonly used to assess DOX-induced cell death. A challenge arises from DOX's intrinsic fluorescence, which interferes with accurate detection. To address this, we successfully used DRAQ7, a far-red dye, in HeLa and other cancer cell lines. As our study demonstrates DRAQ7 eliminates auto-fluorescence interference, this approach offers precise differentiation of apoptotic cells and improving experimental and therapeutic reliability.
Reference Key
openalex_W7161971856 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yusuf Cem Çiftçi, Ipek Erdogan Vatansever, Bünyamin Akgül
Journal Biology Methods and Protocols
Year 2026
DOI
10.1093/biomethods/bpag025
URL
https://doi.org/10.1093/biomethods/bpag025
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.